Back To: Home : Featured Technology : Microbiome

CLICK HERE FOR WHAT'S NEW IN:
 

Vela Labs, Evercyte to cooperate on cell lines
October 2013
SHARING OPTIONS:

VIENNA, AustriaŚVela Labs and Evercyte have begun a cooperation for the commercialization of immortalized target cells for characterizing biosimilars in a GMP environment. The two companies will develop product-tailored bioassays. A VEGF- responsive cell line has already been provided for testing the potency of Avastin (bevacizumab) biosimilars.
 
"The need of product-relevant cell lines that can be standardized is ever increasing in view of restrictions on the use of laboratory animal as well as the increased demand for analyzing the biological activity of biosimilars and biopharmaceuticals," said Dr. Johannes Grillari, Evercyte's co-founder and chief scientific officer. "Therefore, our cooperation aims to introduce Evercyte's cell lines into the GMP environment and to establish novel, relevant cell lines, including innovative reporter cell lines, for specific biopharmaceuticals, again for use under GMP conditions. "

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.